| Summary: | The aim of this study was to investigate the effectiveness of SGLT2 inhibitors with regard to metabolic parameters and patient safety under routine ambulatory conditions. Retrospective longitudinal study of 95 patients with type 2 diabetes (diabetes duration 13.3 y; HbA1c 8.9%; eGFR 80.1 mL/min) receiving SGLT-2-inhibitors. Metabolic control and adverse event profile were evaluated. The mean follow-up time was 1.2 ± 0.8 years. The following changes were observed: HbA1c −1.0% ± 1.9 (<i>p</i> < 0.001), eGFR −7.0 mL/min ± 13.3 (<i>p</i> < 0.001), albuminuria −23.9 mg/g creatinine ± 144.5 (<i>p</i> = 0.118), bodyweight −3.0 kg ± 5.8 (<i>p</i> < 0.001), systolic blood pressure −6 mmHg ± 22 (<i>p</i> = 0.01), diastolic blood pressure −2 mmHg ± 14 (<i>p</i> = 0.243). 53 participants continuously applied the therapy. Twenty-eight participants discontinued SGLT-2-inhibitors due to various reasons: 20 participants because of genital- or urinary tract infections. One for dysuria, seven due to reduced eGFR below 45 mL/min. This study showed a considerable reduction of HbA1c and a modest reduction of eGFR, bodyweight and systolic blood pressure under clinical routine conditions. Genital infections occurred markedly more often than in randomized controlled trials. To apply SGLT-2-inhibitors more safely in clinical routine individual risks for genital and urinary tract infections should be considered and re-evaluated during therapy.
|
|---|